专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07189400B2 Methods of treatment with antagonists of MU-1 有权
标题翻译：用MU-1拮抗剂治疗的方法
公开(公告)号：US07189400B2
公开(公告)日：2007-03-13
申请号：US09972218
申请日：2001-10-04
申请人： Laura Carter , Matthew J. Whitters , Mary Collins , Deborah A. Young , Debra D. Donaldson , Lesile D. Lowe , Michelle Unger
发明人： Laura Carter , Matthew J. Whitters , Mary Collins , Deborah A. Young , Debra D. Donaldson , Lesile D. Lowe , Michelle Unger
IPC分类号： A61K39/00 , A61K39/315 , A61K38/17
CPC分类号： A61K38/20 , A61K38/00 , C07K14/715 , C07K2319/30
摘要： Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein.
摘要翻译：提供了通过施用MU-1造血细胞因子受体超家族蛋白质的拮抗剂来抑制受试者的免疫应答的方法。

2. 发明授权

US07198789B2 Methods and compositions for modulating interleukin-21 receptor activity 有权
标题翻译：用于调节白细胞介素-21受体活性的方法和组合物
公开(公告)号：US07198789B2
公开(公告)日：2007-04-03
申请号：US10264634
申请日：2002-10-04
申请人： Laura Carter , Beatriz Carreno , Leslie D. Lowe , Matthew J. Whitters , Kyri Dunussi , Mary Collins , Margery Ma , Deborah A. Young , JoAnn S. Witek , Glenn Larsen , Marion T. Kasaian , Debra D. Donaldson , Michelle Unger
发明人： Laura Carter , Beatriz Carreno , Leslie D. Lowe , Matthew J. Whitters , Kyri Dunussi , Mary Collins , Margery Ma , Deborah A. Young , JoAnn S. Witek , Glenn Larsen , Marion T. Kasaian , Debra D. Donaldson , Michelle Unger
IPC分类号： A61K39/00 , A61K39/395 , A61K38/17
CPC分类号： C07K14/715 , A61K38/1793 , A61K38/20 , C07K2319/30
摘要： Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
摘要翻译：使用IL-21或IL-21受体（“IL-21R”或“MU-1”）的激动剂或拮抗剂调节白细胞介素-21（IL-21）/ IL-21受体（MU-1）活性的方法和组合物，被披露。 IL-21 / IL-21R拮抗剂可用于在体内诱导免疫抑制，例如用于治疗或预防免疫细胞相关病理学（例如，与一种或多种成熟T细胞的异常活性相关的病理学（成熟CD8 +，成熟 CD4 + T细胞），成熟NK细胞，B细胞，巨噬细胞和巨核细胞，包括移植排斥反应和自身免疫性疾病。 IL-21 / IL-21R激动剂可以自身使用或与抗原组合使用，例如作为佐剂（例如，疫苗佐剂），以在体内上调免疫应答，例如使用在治疗癌症和感染性疾病。

3. 发明授权

US6057128A MU-1, member of the cytokine receptor family 失效
公开(公告)号：US6057128A
公开(公告)日：2000-05-02
申请号：US040005
申请日：1998-03-17
申请人： Debra D. Donaldson , Michelle Unger
发明人： Debra D. Donaldson , Michelle Unger
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61K48/00 , A61P7/06 , A61P35/00 , A61P37/02 , C07K14/715 , C07K16/28 , C12N5/10 , C12N15/12 , C12P21/02 , C12N15/62
CPC分类号： C07K14/715 , A61K38/00 , C07K2319/30
摘要： Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.

4. 发明授权

US07705123B2 MU-1, member of the cytokine receptor family 有权
标题翻译： MU-1，细胞因子受体家族的成员
公开(公告)号：US07705123B2
公开(公告)日：2010-04-27
申请号：US11957891
申请日：2007-12-17
申请人： Debra D. Donaldson , Michelle J. Unger
发明人： Debra D. Donaldson , Michelle J. Unger
IPC分类号： C07K14/715 , C07K19/00 , C12N15/62
CPC分类号： C07K14/715 , A61K38/00 , C07K2319/30 , Y02A50/409 , Y02A50/411
摘要： Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.
摘要翻译：公开了编码MU-1造血细胞因子受体超家族链及其片段的多核苷酸。还公开了MU-1蛋白质及其生产方法。

5. 发明授权

US07615213B2 Antibodies against human interleukin-13 and pharmaceutical compositions thereof 失效
标题翻译：针对人白细胞介素-13的抗体及其药物组合物
公开(公告)号：US07615213B2
公开(公告)日：2009-11-10
申请号：US11149309
申请日：2005-06-09
申请人： Marion T. Kasaian , Lioudmila Tchistiakova , Geertruida M. Veldman , Kimberly Ann Marquette , Xiang-Yang Tan , Debra D. Donaldson , Laura Long Lin , Tania Shane , Amy Sze Pui Tam , Eric Feyfant , Nancy L. Wood , Lori J. Fitz , Angela M. Widom , Kevin D. Parris , Samuel J. Goldman , Jose W. Saldanha
发明人： Marion T. Kasaian , Lioudmila Tchistiakova , Geertruida M. Veldman , Kimberly Ann Marquette , Xiang-Yang Tan , Debra D. Donaldson , Laura Long Lin , Tania Shane , Amy Sze Pui Tam , Eric Feyfant , Nancy L. Wood , Lori J. Fitz , Angela M. Widom , Kevin D. Parris , Samuel J. Goldman , Jose W. Saldanha
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.
摘要翻译：本申请涉及结合白细胞介素-13（IL-13）特别是人IL-13的抗体，例如人源化抗体及其抗原结合片段，以及它们在调节由IL-13介导的免疫应答中的用途。本文公开的抗体可用于诊断，预防和/或治疗受试者，例如人类患者，一种或多种IL-13相关疾病，例如呼吸系统疾病（例如哮喘）; 特应性疾病（如过敏性鼻炎）; 皮肤的炎症和/或自身免疫病症（例如特应性皮炎）和胃肠器官（例如炎性肠病（IBD））以及纤维化和癌性疾病。

6. 发明申请

US20080076120A1 Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders 审中-公开
标题翻译：用于鉴定，评估和治疗患有CC趋化因子受体2（CCR-2）介导的疾病的患者的方法
公开(公告)号：US20080076120A1
公开(公告)日：2008-03-27
申请号：US11522273
申请日：2006-09-14
申请人： Debra D. Donaldson , Alexander N. Parker
发明人： Debra D. Donaldson , Alexander N. Parker
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/6827 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present invention is directed to the identification of predictive genotypes, e.g., predictive single nucleotide polymorphisms (SNPs), and markers that can be used to determine whether a patient having a CC-Chemokine Receptor 2 (CCR-2) mediated disorders is likely to be responsive or non-responsive to a therapeutic regimen. For example, the present invention is directed, in part, to the use of certain individual and/or combinations of SNPs, wherein the expression of particular alleles at particular SNPs, or combinations of alleles at loci in linkage disequilibrium with a particular SNP, correlate with responsiveness or non-responsiveness to a therapeutic regimen. The present invention is also directed to the use of certain individual and/or combinations of predictive markers which correlate with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining allelic expression at particular SNPs, combinations of alleles at loci in linkage disequilibrium with a particular SNP, or expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a patient having a CCR-2 mediated disorder will likely respond or not respond to a therapeutic regimen.
摘要翻译：本发明涉及预测基因型的鉴定，例如预测性单核苷酸多态性（SNPs）和可用于确定具有CC趋化因子受体2（CCR-2）介导的病症的患者是否可能对治疗方案有反应或不响应。例如，本发明部分地涉及SNP的某些个体和/或组合的使用，其中特定SNP的特定等位基因的表达或与特定SNP的连锁不平衡的基因座处的等位基因的组合相关对治疗方案的反应或不响应。本发明还涉及与治疗方案的反应性或非反应性相关的预测标记的某些个体和/或组合的用途。因此，通过检查特定SNP处的等位基因表达，与特定SNP连锁不平衡的位点处的等位基因的组合，或包含标志物组的个体预测标记物和/或预测标记物的表达水平，可以确定是否具有 CCR-2介导的病症可能对治疗方案有反应或不响应。

7. 发明申请

US20100129360A1 ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 AND USES THEREFOR 有权
标题翻译：抗体人类抗体13及其用途
公开(公告)号：US20100129360A1
公开(公告)日：2010-05-27
申请号：US12575896
申请日：2009-10-08
申请人： Marion T. Kasaian , Lioudmila Gennadievna Tchistiakova , Geertruida Machteld Veldman , Kimberly Ann Marquette , Xiang-Yang Tan , Debra D. Donaldson , Laura Long Lin , Tania Shane , Amy Sze Pui Tam , Eric Feyfant , Nancy L. Wood , Lori J. Fitz , Angela M. Widom , Kevin D. Parris , Samuel J. Goldman , Jose W. Saldanha
发明人： Marion T. Kasaian , Lioudmila Gennadievna Tchistiakova , Geertruida Machteld Veldman , Kimberly Ann Marquette , Xiang-Yang Tan , Debra D. Donaldson , Laura Long Lin , Tania Shane , Amy Sze Pui Tam , Eric Feyfant , Nancy L. Wood , Lori J. Fitz , Angela M. Widom , Kevin D. Parris , Samuel J. Goldman , Jose W. Saldanha
IPC分类号： A61K39/395 , C07K16/24 , C07K16/18 , C07H21/00 , C12N5/10 , C12P21/00 , G01N33/543 , A61P37/02
CPC分类号： C07K16/244 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.
摘要翻译：本申请涉及结合白细胞介素-13（IL-13）特别是人IL-13的抗体，例如人源化抗体及其抗原结合片段及其在调节由IL-13介导的免疫应答中的用途。本文公开的抗体可用于诊断，预防和/或治疗受试者，例如人类患者，一种或多种IL-13相关疾病，例如呼吸系统疾病（例如哮喘）; 特应性疾病（如过敏性鼻炎）; 皮肤的炎症和/或自身免疫病症（例如特应性皮炎）和胃肠器官（例如炎性肠病（IBD））以及纤维化和癌性疾病。

8. 发明申请

US20090214516A1 Inhibitors of Reglll Proteins as Asthma Therapeutics 审中-公开
标题翻译： Reglll蛋白抑制剂作为哮喘治疗药物
公开(公告)号：US20090214516A1
公开(公告)日：2009-08-27
申请号：US11628255
申请日：2005-06-03
申请人： Maximillian T. Follettie , Debra D. Donaldson
发明人： Maximillian T. Follettie , Debra D. Donaldson
IPC分类号： A61K39/395 , G01N33/53 , C12Q1/68 , A61K31/7088
CPC分类号： C07K14/474 , C07K2319/30 , G01N33/74 , G01N2500/04 , G01N2800/122
摘要： Methods of screening for agents for treating asthma are provided. The methods involve screening for agents that decrease the production or activity of a RegIII protein that has been discovered herein to play a role in producing the symptoms and pathological complications involved in asthma. Methods of treating asthma, as well as screening for and treating with inhibitors of a RegIII protein are also provided.
摘要翻译：提供了用于治疗哮喘的药物的筛选方法。所述方法包括筛选降低本文发现的RegIII蛋白的产生或活性以在产生与哮喘有关的症状和病理并发症中发挥作用的药剂。还提供了治疗哮喘的方法，以及用RegIII蛋白抑制剂的筛选和治疗。

9. 发明授权

US07501121B2 IL-13 binding agents 失效
标题翻译： IL-13结合剂
公开(公告)号：US07501121B2
公开(公告)日：2009-03-10
申请号：US11155843
申请日：2005-06-17
申请人： Lioudmila Tchistiakova , Marion T. Kasaian , Debra D. Donaldson , Xiang-Yang Tan , Davinder Gill , Macy X. Jin , Bruce Jacobson , Samuel J. Goldman , John Knopf , Angela M. Widom
发明人： Lioudmila Tchistiakova , Marion T. Kasaian , Debra D. Donaldson , Xiang-Yang Tan , Davinder Gill , Macy X. Jin , Bruce Jacobson , Samuel J. Goldman , John Knopf , Angela M. Widom
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92
摘要： Agents (e.g., antibodies and fragments thereof) that bind specifically to IL 13 and modulate the ability of IL-13 to interact with IL-13 receptors and signaling mediators are disclosed.
摘要翻译：公开了特异性结合IL13并调节IL-13与IL-13受体和信号传导介质相互作用的能力的试剂（例如抗体及其片段）。

10. 发明授权

US07994292B2 MU-1, member of the cytokine receptor family 有权
标题翻译： MU-1，细胞因子受体家族的成员
公开(公告)号：US07994292B2
公开(公告)日：2011-08-09
申请号：US12695485
申请日：2010-01-28
申请人： Debra D. Donaldson , Michelle J. Unger
发明人： Debra D. Donaldson , Michelle J. Unger
IPC分类号： C07K16/28 , C07K14/705
CPC分类号： C07K14/715 , A61K38/00 , C07K2319/30 , Y02A50/409 , Y02A50/411
摘要： Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins, antibodies (and fragments thereof) that specifically bind to MU-1 proteins (and fragments thereof), and methods for their production are also disclosed.
摘要翻译：公开了编码MU-1造血细胞因子受体超家族链及其片段的多核苷酸。还公开了MU-1蛋白质，其特异性结合MU-1蛋白质（及其片段）的抗体（及其片段）及其生产方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式